MX343683B - El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico. - Google Patents
El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico.Info
- Publication number
- MX343683B MX343683B MX2013014174A MX2013014174A MX343683B MX 343683 B MX343683 B MX 343683B MX 2013014174 A MX2013014174 A MX 2013014174A MX 2013014174 A MX2013014174 A MX 2013014174A MX 343683 B MX343683 B MX 343683B
- Authority
- MX
- Mexico
- Prior art keywords
- prolactin receptor
- benign
- receptor antibody
- prevention
- treatment
- Prior art date
Links
- 108010002519 Prolactin Receptors Proteins 0.000 title abstract 4
- 102100029000 Prolactin receptor Human genes 0.000 title abstract 4
- 101100495256 Caenorhabditis elegans mat-3 gene Proteins 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000005641 Adenomyosis Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006298 Breast pain Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000006662 Mastodynia Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000011803 breast fibrocystic disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 1
- 230000008556 epithelial cell proliferation Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000006651 lactation Effects 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a el anticuerpo neutralizador del receptor de prolactina Mat3. Fragmentos de unión al antígeno de éste. Composiciones farmacéuticas que contienen dicho anticuerpo o dichos fragmentos de unión al antígeno. Su uso en el tratamiento o la prevención de las afecciones y los trastornos benignos que son mediados por el receptor de prolactina, tales como la endometriosis, la adenomiosis, las enfermedades benignas de las mamas, la mastalgia, la hiperplasia prostática benigna, los fibroides o la pérdida de cabello hiperprolactinémica o normoprolactinémica, en la inhibición de la lactancia, en la anticoncepción femenina no hormonal, en una terapia hormonal combinada, en la inhibición de la proli-feración de las células de las mamas o en el tratamiento o la prevención del cáncer de mama resistente a los agentes antiestrogénicos. El anticuerpo de acuerdo con la invención bloquea la señalización que es mediada por el receptor de prolactina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168644A EP2530089A1 (en) | 2011-06-03 | 2011-06-03 | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| PCT/EP2012/060078 WO2012163932A1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014174A MX2013014174A (es) | 2014-11-13 |
| MX343683B true MX343683B (es) | 2016-11-17 |
Family
ID=46331236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014174A MX343683B (es) | 2011-06-03 | 2012-05-31 | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9353186B2 (es) |
| EP (2) | EP2530089A1 (es) |
| JP (1) | JP5859641B2 (es) |
| KR (1) | KR101920521B1 (es) |
| CN (1) | CN103764679B (es) |
| AP (1) | AP2013007266A0 (es) |
| AR (1) | AR086631A1 (es) |
| AU (1) | AU2012264765B2 (es) |
| BR (1) | BR112013030995B1 (es) |
| CA (1) | CA2837736C (es) |
| CL (1) | CL2013003459A1 (es) |
| CO (1) | CO6852025A2 (es) |
| CR (1) | CR20130632A (es) |
| CU (1) | CU20130163A7 (es) |
| CY (1) | CY1117660T1 (es) |
| DK (1) | DK2714740T3 (es) |
| DO (1) | DOP2013000285A (es) |
| EA (1) | EA029316B1 (es) |
| EC (1) | ECSP13013063A (es) |
| ES (1) | ES2572215T3 (es) |
| HR (1) | HRP20160506T1 (es) |
| HU (1) | HUE028775T2 (es) |
| IL (1) | IL229504B (es) |
| MA (1) | MA35237B1 (es) |
| ME (1) | ME02659B (es) |
| MX (1) | MX343683B (es) |
| PE (1) | PE20141158A1 (es) |
| PH (1) | PH12013502494A1 (es) |
| PL (1) | PL2714740T3 (es) |
| RS (1) | RS54727B1 (es) |
| SG (1) | SG195060A1 (es) |
| SI (1) | SI2714740T1 (es) |
| TN (1) | TN2013000501A1 (es) |
| TW (1) | TWI548649B (es) |
| UY (1) | UY34116A (es) |
| WO (1) | WO2012163932A1 (es) |
| ZA (1) | ZA201309683B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114133454A (zh) | 2012-03-14 | 2022-03-04 | 瑞泽恩制药公司 | 多特异性抗原结合分子及其用途 |
| TW201920245A (zh) * | 2012-12-24 | 2019-06-01 | 美商艾伯維有限公司 | 催乳激素受體結合蛋白質及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| ES2971045T3 (es) | 2015-07-06 | 2024-06-03 | Regeneron Pharma | Moléculas multiespecíficas de unión a antígeno y usos de las mismas |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| US10925971B2 (en) | 2016-11-29 | 2021-02-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating PRLR positive breast cancer |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| KR20200027494A (ko) | 2017-07-10 | 2020-03-12 | 바이엘 파마 악티엔게젤샤프트 | 남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체 |
| PL3587445T3 (pl) * | 2017-08-10 | 2024-04-29 | Grifols Diagnostic Solutions Inc. | ZNACZNIK OLIGOMERYZACJI ZAWIERAJĄCY REGION Fc IMMUNOGLOBULINY I DOMENĘ POLYHIS |
| EP3749373A1 (en) | 2018-02-07 | 2020-12-16 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4428150A1 (en) | 2023-03-07 | 2024-09-11 | Peptide Logic LLC | Antibody or antigen-binding fragment thereof |
| CN116655791B (zh) * | 2023-05-06 | 2023-11-07 | 浙江触奇生物科技有限公司 | 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| EP2083088A3 (en) | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| GEP20125612B (en) * | 2006-08-18 | 2012-08-27 | Novartis Ag | Prlr-specific antibody and usage thereof |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
-
2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
-
2012
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en not_active Ceased
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 PH PH1/2013/502494A patent/PH12013502494A1/en unknown
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active Active
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active IP Right Grant
-
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
-
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502494A1 (en) | Neutralizing prolactin receptor antibody mat3 and its therapeutic use | |
| TN2012000294A1 (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX2019000586A (es) | Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd). | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. | |
| TN2014000247A1 (en) | 6,7-dihydro-5h-benzo[7]annulene derivatives, methods for the production thereof, pharmaceutical preparations that contain said 6,7-dihydro-5h-benzo[7]annulene derivatives, and use thereof to produce drugs | |
| IN2015MN00001A (es) | ||
| MX364985B (es) | Antagonistas de imidazolil progesterona. | |
| TW201613615A (en) | Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy | |
| EA201491344A1 (ru) | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона | |
| HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use | |
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| WO2010104691A3 (en) | Estrogenic compounds and their methods of use | |
| PH12014501202A1 (en) | Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |